Latest Safety News

Lotus Resources has secured Environmental and Social Impact Assessment approval for its Kayelekera Uranium Project in Malawi, paving the way for uranium production to resume in the third quarter of 2025. The company also completed a key board transition, signaling a new phase in its governance.

Lindian Resources reports significant construction progress at its Kangankunde Rare Earths Project in Malawi, alongside strategic site leadership appointments as it gears up for plant construction later this year.

Nyrada has secured ethics approval to amend its Phase I clinical trial protocol for Xolatryp, allowing testing of higher doses and extended infusion times. This strategic move aims to refine dosing ahead of Phase II trials, with final Phase I results expected by September 2025.

Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.

Radiopharm Theranostics has initiated dosing in its Phase 1 HEAT trial of 177Lu-RAD202, a novel radiotherapeutic aimed at advanced HER2-positive solid tumors, marking a key step in its clinical development.

I Synergy Group Limited has announced a fully underwritten pro-rata renounceable entitlement offer to raise up to $1 million, aiming to bolster working capital and fund key operational initiatives. The offer, underwritten by VGI Vmall Limited, will significantly increase the company's shares on issue, with potential dilution risks for non-participating shareholders.

I Synergy Group Limited has announced a renounceable entitlement offer aiming to raise approximately $1 million to fund new projects and operational growth. The offer is fully underwritten and open to shareholders across multiple Asia-Pacific markets.

Black Cat Syndicate reports robust operational progress at its Kal East Gold Operation, surpassing expectations at the Lakewood processing facility and achieving early cash flow positivity at the Myhree open pit. Development activities at Majestic and Fingals advance as the company expands production capacity.

Life360 has increased its convertible notes offering to $275 million, introducing capped call transactions to manage dilution risks as it prepares for potential growth investments.

InhaleRx has secured swift Human Research Ethics Committee approval for its redesigned IRX-211 Phase 2 trial, expanding participant numbers and potentially bypassing Phase 3 to speed market entry.

Paradigm Biopharmaceuticals has reached key milestones in its global Phase 3 trial for knee osteoarthritis, activating its first Australian clinical site and enrolling the first patient. With multiple sites in Australia and the US preparing for recruitment, the trial is advancing steadily toward critical data readouts.

Life360 has announced a $250 million convertible senior notes offering, with an option for an additional $37.5 million, aiming to bolster its balance sheet and support strategic initiatives.